Literature DB >> 3040855

A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha.

P Seckinger, K Williamson, J F Balavoine, B Mach, G Mazzei, A Shaw, J M Dayer.   

Abstract

Urine from monocytic leukemia and other febrile patients contains an inhibitor of interleukin 1 (IL-1), as measured by prostaglandin E2 and collagenase production by human fibroblasts and synovial cells. With the use of recombinant IL-1, the IL-1 inhibitor was partially purified by using ammonium sulfate precipitation, anion-exchange, and gel filtration chromatographies. IL-1 inhibitory activity elutes with an 18,000 to 25,000 apparent molecular size. The same fractions also inhibit IL-1 assayed by the proliferation of murine thymocytes and human fibroblasts. Both forms of human recombinant IL-1, IL-1 alpha and IL-1 beta, which show only 26% homology, but nevertheless bind to the same receptor, are affected by this natural inhibitor to the same extent. In contrast, human recombinant tumor necrosis factor, which shares some of the biologic activities of IL-1, is not inhibited by the urinary IL-1 inhibitor. This study shows that the various biologic activities of both forms of human recombinant IL-1 are inhibited by a partially purified natural urine-derived factor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040855

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Glucocorticoid-induced keratinocyte-derived interleukin-1 receptor antagonist(s).

Authors:  S Stosić-Grujicić; M L Lukić
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

2.  Elevated cytokine and chemokine levels in the placenta are associated with in-utero HIV-1 mother-to-child transmission.

Authors:  Surender B Kumar; Cara E Rice; Danny A Milner; Nilsa C Ramirez; William E Ackerman; Victor Mwapasa; Abigail Norris Turner; Jesse J Kwiek
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

3.  Inhibitor of interleukin-1 alpha and interleukin-1 beta-induced T-cell activation in serum of patients with active Crohn's disease.

Authors:  J Brynskov; M B Hansen; C Reimert; K Bendtzen
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

Review 4.  The role of cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  P E Lipsky; L S Davis; J J Cush; N Oppenheimer-Marks
Journal:  Springer Semin Immunopathol       Date:  1989

Review 5.  Interleukin-1 function and role in rheumatic disease.

Authors:  Georg Schett; Jean-Michel Dayer; Bernhard Manger
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

6.  Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study.

Authors:  Maren Carstensen; Christian Herder; Mika Kivimäki; Markus Jokela; Michael Roden; Martin J Shipley; Daniel R Witte; Eric J Brunner; Adam G Tabák
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

7.  Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls.

Authors:  S Ruschen; W Stellberg; H Warnatz
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

8.  Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Jan A Ehses; Zoltan Mathe; Domenico Bosco; Thierry Berney; Jean-Michel Dayer; Manfred Reinecke; Philippe A Halban; Marc Y Donath
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-12       Impact factor: 11.205

9.  The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia.

Authors:  Nadine S Sauter; Fabienne T Schulthess; Ryan Galasso; Lawrence W Castellani; Kathrin Maedler
Journal:  Endocrinology       Date:  2008-01-31       Impact factor: 4.736

10.  Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival.

Authors:  R Glas; N S Sauter; F T Schulthess; L Shu; J Oberholzer; K Maedler
Journal:  Diabetologia       Date:  2009-04-25       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.